The Efficacy of Botulinum Toxin in Cluster Headache: A Systematic Review

Aims: To conduct a systematic review of the literature on the use of botulinum toxin for the treatment of cluster headache. Methods: A systematic review and data quality analysis were performed using PRISMA and GRADE guidelines, respectively. Inclusion and exclusion criteria were outlined prior to the search and aimed to select prospective studies that examined the use of botulinum toxin for the treatment of cluster headache. Results: Three studies resulted from the search that each included 10 to 17 subjects. All three demonstrated significant improvement in the frequency of headaches that occurred as quickly as 1 week following treatment. There was low-quality evidence that botulinum toxin was effective in reducing headache frequency and severity by at least 50%. Injections into the sphenopalatine ganglion may have a higher incidence of adverse events. Conclusion: This review summarizes the only prospectively collected efficacy and safety data regarding the use of botulinum toxin in cluster headache. Off-label use should be considered in certain cases. Further study is warranted to better characterize injection paradigms and patient selection, given the encouraging but limited data available.

botox; botulinum toxin; cluster headache

1. Ailani J, Young WB. The role of nerve blocks and botulinum toxin injections in the management of cluster headaches. CurrPain Headache Rep 2009;13:164–167.

2. Hoffmann J, May A. Diagnosis, pathophysiology, and manage-ment of cluster headache. Lancet Neurol 2018;17:75–83.

3. Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis.Headache 1990;30:411–417.

4. Steiner TJ, Hering R, Couturier EG, Davies PT, Whitmarsh TE. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997;17:673–675.

5. Leone M, Dodick D, Rigamonti A, D’Amico D, Grazzi L, Mea E, Bussone G. Topiramate in cluster headache prophylaxis: An open trial. Cephalalgia 2003;23:1001–1002.

6. Gaul C, Finken J, Biermann J, et al. Treatment costs and indirect costs of cluster headache: A health economics analysis. Cephalalgia 2011;31:1664–1672.

7. Escher CM , Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: Clinical evidence and experience. Ther Adv Neurol Disord 2017;10:127–135.

8. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465–1472.

9. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004; 279:25665–25672.

10. Shimizu T, Shibata M, Toriumi H, et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 2012;48:367–378.

11. Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015;156:820–824.

12. Moher D , Shamseer L , Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

13. Lipton RB, Micieli G, Russell D, Solomon S, Tfelt-Hansen P, Waldenlind E. Guidelines for controlled trials of drugs in clus-ter headache. Cephalalgia 1995;15:452–462.

14. Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group. https://figshare.com/articles/How_to_GRADE/6818894. La Trobe University, Melbourne: 2016. Accessed 28 May 2019.

15. Lampl C, Rudolph M, Bräutigam E. OnabotulinumtoxinA in the treatment of refractory chronic cluster headache. J Headache Pain 2018;19:45.

16. Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: An open study. J Headache Pain 2007;8:236–241.

17. Bratbak DF, Nordgård S, Stovner LJ, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatmentof intractable chronic cluster headache. Cephalalgia 2016;36:503–509.

18. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793–803.

19. Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: The American Headache Society Evidence-Based Guidelines. Headache 2016;56: 1093–1106.

20. Freund BJ, Schwartz M. The use of Botulinum toxin-A in the treatment of refractory cluster headache: Case reports. Cephalalgia 2000;20:325–331.

21. Robbins L. Botulinum toxin A (Botox) for cluster headache: 6 cases. Cephalalgia 2001;21:499–500.

22. Smuts JA, Barnard PWA. Botulinum toxin type A in the treatment of headache syndromes: A clinical report of 79 patients. Cephalalgia 2000;20:332.

23. Cesaretti C, De Cesaris F, Amantini A, Lori S. Botulinum toxin type-A therapy in cluster headache: Two clinical cases. Clin Neurophysiol 2016;127:e337.

24. Roznieck JJ, Durko A. Botulinum toxin type A in the treatment of episodic and chronic form of cluster headache. Cephalalgia 2013;33(suppl 1):s108–s109.

25. Finiels PJ, Batifol D. Total relief of cluster headache after Botulinum toxin injection: Case report. J Ear Nose Throat Disord 2017;2:1023.

26. Spencer SE, Sawyer WB, Wada H, Platt KB, Loewy AD. CNS projections to the pterygopalatine parasympathetic preganglionic neurons in the rat: A retrograde transneuronal viral cell body labeling study. Brain Res 1990;534:149–169.

27. Goadsby PJ. Autonomic nervous system control of the cerebral circulation. In: Buijis RM, Swaab DF (eds). Autonomic Nervous System: Handbook of Clinical Neurology, volume 117. Amsterdam: Elsevier, 2013:193–201.

28. Goadsby PJ, Lambert GA, Lance JW. The peripheral pathway for extracranial vasodilation in the cat. J Auton Nerv Syst 1984;10:145–155.

29. Ashkenazi A, Schwedt T. Cluster headache—Acute and pro-phylactic therapy. Headache 2011;51:272–286.

30. May A. Cluster headache: Pathogenesis, diagnosis, and management. Lancet 2005;366:843–855.

31. Aschehoug I, Bratbak DF, Crespi J, Dodick DW, Tronvik EA. Injection of onabotulinum toxin A towards the sphenopalatine ganglion—A potential long-term treatment for chronic cluster headache patients? [Abstract.] Cephalalgia 2017;37:1 (suppl 1)s173–s174.